TEASE Program Builds Case for Gildeuretinol in Stargardt - Top-Institutions - MDSpire

TEASE Program Builds Case for Gildeuretinol in Stargardt

Philip J. Ferrone, MD, FASRS, reviewed data on gildeuretinol and discussed the ongoing NORTHSTAR pivotal trial at Retina World Congress.

  • By

  • Philip Ferrone, MD

  • May 14, 2026

  • 3 min

Share

Top Institutions in Ophthalmology

Brief introduction explaining scope and methodology.

  • #1

    Bascom Palmer Eye Institute, University of Miami
    Bascom Palmer Eye Institute, University of Miami

    Miami, Florida

    Key Differentiators

    • Ophthalmology
    • Inherited Retinal Diseases
    • Gene Therapy

  • #2

    Wilmer Eye Institute, Johns Hopkins Medicine
    Wilmer Eye Institute, Johns Hopkins Medicine

    Baltimore, Maryland

    Key Differentiators

    • Ophthalmology
    • Inherited Retinal Diseases

  • #3

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Ophthalmology

  • #4

    New York Eye and Ear Infirmary of Mount Sinai
    New York Eye and Ear Infirmary of Mount Sinai

    New York, New York

    Key Differentiators

    • Ophthalmology

  • #5

    Institute of Molecular and Clinical Ophthalmology Basel
    Institute of Molecular and Clinical Ophthalmology Basel

    Basel, Switzerland

    Key Differentiators

    • Ophthalmology
    • Gene Therapy

Original Source(s)

TEASE Program Builds Case for Gildeuretinol in Stargardt

  • by Philip Ferrone, MD

  • May 14, 2026

Related Content

A fluoride shortage for some U.S. water systems

One hotspot RB1 mutation disrupt RB1 function founded in a Chinese patient

Rapid evaporative ionization mass spectrometry in surgery: a systematic review